Does SECUKINUMAB Cause Hepatic steatosis? 308 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 308 reports of Hepatic steatosis have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.2% of all adverse event reports for SECUKINUMAB.
308
Reports of Hepatic steatosis with SECUKINUMAB
0.2%
of all SECUKINUMAB reports
9
Deaths
102
Hospitalizations
How Dangerous Is Hepatic steatosis From SECUKINUMAB?
Of the 308 reports, 9 (2.9%) resulted in death, 102 (33.1%) required hospitalization, and 13 (4.2%) were considered life-threatening.
Is Hepatic steatosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 308 reports have been filed with the FAERS database.
What Other Side Effects Does SECUKINUMAB Cause?
Drug ineffective (27,434)
Psoriasis (21,976)
Pain (15,244)
Arthralgia (13,769)
Fatigue (9,406)
Psoriatic arthropathy (8,900)
Pruritus (8,755)
Malaise (8,570)
Rash (8,023)
Condition aggravated (7,536)
What Other Drugs Cause Hepatic steatosis?
METHOTREXATE (1,400)
ADALIMUMAB (1,058)
ETANERCEPT (620)
TOCILIZUMAB (476)
TOFACITINIB (405)
LEFLUNOMIDE (359)
HYDROXYCHLOROQUINE (358)
ABATACEPT (345)
METFORMIN (343)
INFLIXIMAB (325)
Which SECUKINUMAB Alternatives Have Lower Hepatic steatosis Risk?
SECUKINUMAB vs SELADELPAR LYSINE
SECUKINUMAB vs SELEGILINE
SECUKINUMAB vs SELENIUM
SECUKINUMAB vs SELENIUM SULFIDE
SECUKINUMAB vs SELEXIPAG